Thyroglobulin ELISA

Key Features and Values

– Same sample type can be used across all assays to simplify inclusion into routine serology work-up
– Ready to use reagents reduces hands-on time for assay preparation
– Long shelf life cost-effective solution by reducing wastage due to expired kits
– Suitable for inclusion on automated plate systems simplifies scale-up of test volume
– Supported by a complete panel of assays for supporting treatment monitoring of several forms of hormonal dysfunctions

Product Description

Immunoenzymatic colorimetric method for the quantitative determination of Thyroglobulin concentration in human serum. Thyroglobulin ELISA kit is intended for laboratory use only.

Scientific Description
Thyroglobulin (TG), a glycoprotein with a molecular weight of about 660,000 Daltons, is the thyroid’s main iodine protein and the most important compound of follicular colloid.  Thyroglobulin is the form under which the active hormones T3 and T4 together with their immediate forerunners MIT and DIT are laid inside the thyroid gland.  The clinical applications of the TG dosage seem to originate from its specificity for the thyroid and related cells.
The dosage of TG can be used as support to scintigraphies or other techniques for studying pathogenesis, making a diagnosis and analysing the course of thyroid disorders.  The dosage of TG before and after replacement treatment with L-Thyroxin cannot be established in cases of hypothyroidism due to thyroid agenesis.  In cases of secondary hypothyroidism with a dysglandular goiter or ectopic thyroid, the levels of TG are normal or high.  The circulating levels of TG tend to increase in several thyroid disorders such as toxic and atoxic goiter, subacute thyroiditis, Basedow’s disease and carcinoma.  In Basedow’s disease the TG dosage is a potentially interesting index of normalisation of hyperthyroidism in patients treated with anti-thyroid drugs.  In the oncology field and more specifically for differentiated thyroid carcinoma, there are very promising applications linked to the ability of thyroid tumours tissues to concentrate iodine and synthesise TG as a normal thyroid.  Basically the dosage of TG can be used as follows:
a. Pre-operating diagnosis of thyroid tumours.
This application does not allow the differentiated diagnosis of the tumour as the values of TG seen in malignant and benign nodules are superimposable.
b. Post-operation monitoring
In patients treated surgically or with radiotherapy, long lasting TG levels suggest the presence of a residual carcinoma and/or carcinoma with metastasis.
c. Monitoring of totally thyroidectomised patients
The use of circulating TG as an indicator of recurrent tumours (metastasis marker) has an established clinical value: the increase of Thyroglobulinaemia indicates the need to undergo further analysis for confirming the diagnosis.
Interesting advantages can come from: a) a reduced use of scintigraphic diagnostic techniques as they imply regular suspension of replacement treatment and frequent exposure to radiation, b) and complete completion of the information obtained via scintigraphy
Publications

1. Beever K, Bradbury J, Phillips D, et al, “Highly sensitive assays of autoantibodies to Thyroglobulin and Thyroid Peroxidase”, Clin Chem, 35, 1949-1954 (1989).
2. Ladenson PW, “Optimal laboratory testing for diagnosis and monitoring of thyroid nodules, goiter, and thyroid cancer”, Clin Chem, 42, 183-187 (1996).
3. Mayo Medical Laboratories: test Catalog, Rochester, MN (1997).
4. Spencer CA, Takeucho M, Kazarosyn M, “Current status and performance goals for serum thyroglobulin assays”, Clin Chem, 42, 164-173 (1996).
5. Tietz N. Ed: Clinical Guide to Laboratory Tests. 3rd Ed. Philadelphia. Saunders (1995).
6. Surks, MI, Chopra, IJ, Mariash, CN, “American Thyroid Association guidelines for use of laboratory tests in thyroid disorders”, JAMA, 263,
1529-1532 (1990).
7. Ng, M., Rajna, A, Khalid, B, ”Enzyme immunoassay for simultaneous measurements of autoantibodies against thyroglobulin and thyroid microsomes in serum”, Clin Chem, 33, 2286-2288 (1987).
8. Spencer, CA, Takeucho M, Kazarosyn M, Wang CC, Guttler RB, Singer PA, et al, “Serum thyroglobulin autoantibodies; prevalence, influence on serum thyroglobulin measurements, and prognostic significance in patients with differentiated thyroid carcinoma”, J Clin Endocrinol Metab, 83, 1121-27 (1998).
9. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT, “Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurements”, Thyroid, 9, 435-41 (1999).
10.Schlumberger M, Baudin E, “Serum thyroglobulin determinations in the follow up of patients with differentiated thyroid carcinoma”, Eur J. Endocrinol, 138, 249-252 (1998).

Download
Please enter your email address to download the DKO048-Thyroglobulin-IFU..pdf
Code: DKO048
Clinical Area:
Incubation: 90+60+15 min
Classification: IVD, CE
Number of Tests: 96
Sample Type: Serum
Sample Volume: 50 μL
Assay Range: 2 - 250 ng/mL